Fastened-duration remedy overcomes long-term negative effects, monetary toxicity in CLL
December 11, 2025
2 min watch
ORLANDO — On this video, Shazia Okay. Nakhoda, MD, discusses “thrilling” knowledge from the CLL-17 trial that confirmed fixed-duration remedy produces comparable outcomes inpreviously untreated power lymphocytic leukemia.
Outcomes introduced at ASH Annual Assembly and Exposition confirmed comparable 3-year progression-free survival charges between steady Bruton tyrosine kinase (BTK) inhibitor monotherapy with ibrutinib (Imbruvica; Johnson & Johnson, Pharmacyclics) and fixed-duration remedy with venetoclax (Venclexta; AbbVie, Genentech) plus obinutuzumab (Gazyva, Genentech) and venetoclax plus ibrutinib .
“The important thing takeaway is that the long-term negative effects of steady BTK inhibitor remedy, in addition to the monetary toxicity that comes with that, may be overcome through the use of these fixed-duration therapies,” Nahkoda, assistant professor of the division of hematology/oncology at Fox Chase Most cancers Heart, informed Healio. “That is thrilling knowledge.”
For extra data:
Shazia Nakhoda, MD, may be reached at Shazia.Nakhoda@fccc.edu.
Sources/Disclosures
Supply:
Healio Interviews
Reference:
- Al-Sawaf O, et al. Summary 1. Introduced at: ASH Annual Assembly and Exposition; Dec. 6-9, 2025; Orlando.
Disclosures:
Nakhoda experiences receiving analysis funding from Serb Prescription drugs and receives honoraria and analysis help from AstraZeneca, BeOne Medicines and Genentech.
Ask a medical query and faucet into Healio AI’s data base.
- PubMed, enrolling/recruiting trials, pointers
- Scientific Steering, Healio CME, FDA information
- Healio’s unique each day information protection of medical knowledge
